Description du projet
Traiter des caillots sanguins dangereux sera bientôt bien plus facile et moins coûteux
Un calcul rénal est douloureux, mais rarement mortel. Les traitements s'échelonnent de l'absorption simple de grandes quantités d’eau à la chirurgie dans les cas difficiles. Lorsqu’il s’agit de caillots dans des veines profondes de l’organisme (thrombose veineuse profonde), les choses sont tout à fait différentes. Les caillots de grande taille peuvent se libérer, se loger dans les artères pulmonaires et les bloquer, entraînant souvent la mort. Des traitements thrombolytiques puissants sont administrés lors de séjours prolongés à l’hôpital, mais ils sont associés à un risque considérablement plus élevé d’hémorragie. VETEX commercialise un nouveau traitement révolutionnaire pour permettre l’élimination d’un caillot, minimisant ainsi l’utilisation de médicaments thrombolytiques. Son succès réduira le fardeau sur les systèmes de soins de santé et améliorera la vie de millions de personnes.
Objectif
Deep Vein Thrombosis is the 3rd leading cardiovascular disease behind heart attack and stroke with 1.2M cases diagnosed each year in the EU and US.
Left untreated, one third of DVT patients will be at risk of clot breaking away causing a Pulmonary Embolism which has a 50% mortality rate. In addition, significant chronic complications often occur such as clot recurrence (30%), chronic limb swelling associated with Post Thrombotic Syndrome (50%), ulceration and amputation.
DVT patients are usually treated with drugs. Anticoagulation therapy alone helps prevent clot extension but it does not remove the clot. Other therapies often involve long hospital stays and often require 24-72 hours in ICU due to the significant bleeding risks associated with heavier duty clot busting (Thrombolytic) drugs. The results are poor for patients with large occulsive clots and who are at risk of bleeding, and extremely expensive for healthcare providers.
Vetex Medical is an early stage medical device based in Ireland that has developed a platform technology that rapidly removes high volumes of clot form the deep veins without the use of thrombolytic drugs, and so will radically challenge the inefficiencies and economics present in the current management of deep vein thrombosis.
Deep Vein Thrombosis in the larger veins of the upper limb represents $600m market opportunity. Interventions in the treatment of DVT have been increasing steadily over the last number of years with growth rates of 15%. This market segment is increasingly ‘on trend’ and set to witness expedited growth over the coming years.
Vetex Medical is ambitious in its’ plan to bring the FreeFlow technology to market in both Europe and the US in 2021, through completion of a Clinical Trial and through securing regulatory approvals to allow market entry. The Vetex Medical Team has the skills and experience to develop and commercialise this novel medical technology and to implement a high
growth strategy.
Champ scientifique
Programme(s)
Régime de financement
SME-2 - SME instrument phase 2Coordinateur
H91 FC85 GALWAY
Irlande
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.